Doctoral candidate, Chief Physician. Registered in Beijing, has been working at Peking University Cancer Hospital since July 1999, currently serving as Deputy Director of the Third Gastrointestinal Ward and Deputy Director of the Hospital Infection Control Department. As a gastrointestinal surgeon, has consistently remained on the front line of clinical practice, engaging in clinical research related to colorectal cancer, including preoperative treatment, surgical procedures, clinicopathological studies, and diagnosis of metastatic tumors. As Deputy Department Director, has diligently fulfilled management responsibilities, performing over 300 surgical procedures annually and accumulating extensive experience in the diagnosis and treatment of gastrointestinal tumors. From 2007 to 2008, served as a visiting scholar in oncological surgery at Hautepierre Hospital, University Louis Pasteur, France. Participated in multiple research projects, including the National 863 High-Tech Program and the National 211 Evidence-Based Medicine Project, and published relevant research papers. Authored or co-authored over 10 papers as first author or corresponding author in domestic and international journals. As Deputy Director of the Hospital Infection Control Department, has conscientiously carried out management duties, playing an active role in the hospital's epidemic prevention and control efforts during the COVID-19 pandemic. Awarded the Third Prize of Beijing Science and Technology Progress Award in 2008. Research Projects: 1. Beijing Cancer Hospital Fund, "Clinical and pathological research of peri-IMA lymph node metastases for locally advanced mid-low rectal cancer following preoperative chemoradiotherapy," 2011-2013, 40,000 RMB, completed, Principal Investigator. 2. Beijing Municipal Health Bureau Funded Project, "Application of modified fat clearing technique to improve the accuracy of pathological evaluation after radiotherapy for rectal cancer," 2010-2012, 40,000 RMB, completed, Principal Investigator. 3. Peking University "211" Science and Technology Plan Funded Project, "Multicenter randomized study of preoperative adjuvant radiotherapy for mid-low rectal cancer," 2003, 300,000 RMB, completed, Participant. 4. National "863" Science and Technology Plan Fund, "Research on targeted drug development for gastric cancer and colorectal cancer and pilot development of anti-ovarian cancer monoclonal antibody radioimmunoimaging diagnosis," 2001, 660,000 RMB, completed, Participant. 5. Peking University Interdisciplinary Biomedical Research Fund, "Establishment of a three-dimensional pelvic image mathematical model for the Chinese population and its application in oncological surgery," 2001, 150,000 RMB, completed, Participant. 6. Beijing Hospital Authority Talent Training Program—"Standardization of surgical procedures and prognostic evaluation of transanal minimally invasive surgery (TAMIS) for rectal tumors" (Yao Yunfeng). First Author or Corresponding Author Publications: Yao YF#, Du CZ, Chen N, Chen P, Gu J, Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis, Dis Colon Rectum, 2014, 57(5): 602-607. (2) Yao YF#, Wang L, Liu YQ, Li JY, Gu J, Lymph node distribution and pattern of metastases in the mesorectum following total mesorectal excision using the modified fat clearing technique, J Clin Pathol, 2011, 64(12): 1073-1077. Li Y, Tan L, Chen N, Liu X, Liang F, Yao Y, Zhang X, Wu A. Neoadjuvant Immunotherapy Alone for Patients With Locally Advanced and Resectable Metastatic Colorectal Cancer of dMMR/MSI-H Status. Dis Colon Rectum. 2024 Nov 1;67(11):1413-1422.